134271-94-6

Usage

Uses

Used in Pharmaceutical Industry:
3-methyl-4-nitro-1H-indole is used as a chemical intermediate for the synthesis of various bioactive compounds. Its unique structure and properties make it a valuable building block in the development of new pharmaceuticals.
Used in Medicinal Chemistry:
3-methyl-4-nitro-1H-indole is used as a potential anti-cancer agent. Its chemical properties allow it to be a promising candidate for the development of new cancer treatments.
Used in Antimicrobial Applications:
3-methyl-4-nitro-1H-indole exhibits potential antimicrobial properties, making it a candidate for use in the development of new antibiotics and antifungal agents.
Used in Anti-inflammatory Applications:
3-methyl-4-nitro-1H-indole also shows potential anti-inflammatory properties, which could be utilized in the development of new anti-inflammatory drugs to treat various inflammatory conditions.

Upstream product

• 99-09-2 3-nitro-aniline 
• 134271-93-5 (E)-1-(3-nitrophenyl)-2-propylidenehydrazine 
• 51516-96-2 3-nitrophenylhydrazine hydrochloride 
• 134271-93-5 1-(3-nitrophenyl)-2-propylidenehydrazine 

Downstream Products

• 873054-44-5 ivacaftor 
• 873056-08-7 (2'-ethoxy-2-aminobiphenyl-4-yl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.